Recombinant Human Interleukin-17 (IL17)
(Cat. No.: C015)
Background:
IL-17 is a potent proinflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice.
As interleukin-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. Interleukin-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.
Description:
Recombinant Human IL-17 produced in E. coli is a single, non-glycosylated polypeptide chain containing 133 amino acids and having a molecular mass of 15256
Quality Control:
Biological Activity: The ED50 as determined by the dose-dependent induction of IL
Purity: Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
Amino-Acid Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Gly-Ile-Thr-Ile.
Endotoxin: Less than 0.1ng/µg (IEU/µg) of rHuIL-17.
Formulation: Lyophilized from a concentrated (1mg/ml) solution containing no additives.
Storage: Lyophilized rHuIL-17 although stable at room temperature for 3 weeks, should be stored desiccated below
Please avoid freeze-thaw cycles.
Reconstitution: It is recommended to reconstitute the lyophilized rHuIL






